Illumina Acquires SomaLogic from Standard BioTools to Expand Proteomics and Multiomics

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Pacific Biosciences Acquires Omniome

July 20, 2021

Biotechnology

Pacific Biosciences (PacBio) signed a definitive agreement to acquire San Diego-based Omniome for approximately $600 million in upfront consideration (9.4 million PacBio shares plus $300 million cash) plus up to $200 million in cash and stock tied to milestones, valuing the deal at about $800 million. The deal — supported by a concurrent $300 million PIPE financing — brings Omniome’s high-accuracy short-read Sequencing-by-Binding technology into PacBio’s portfolio of high-accuracy long-read SMRT sequencing systems to expand PacBio’s capabilities and address high-growth clinical markets such as oncology, transcriptomics and NIPT.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Illumina Acquires Fluent BioSciences

July 9, 2024

Biotechnology

Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.

Kiromic Biopharma Acquires InSilico Solutions

July 26, 2021

Biotechnology

Kiromic Biopharma completed the acquisition of InSilico Solutions via a stock-swap, bringing an in‑house bioinformatics and AI team to support development of its outpatient allogeneic CAR‑T therapies for solid tumors. The deal transfers InSilico’s staff and intellectual assets to Kiromic and is intended to accelerate target/biomarker discovery, manufacturing and clinical development.

QIAGEN to Acquire Parse Biosciences

November 4, 2025

Biotechnology

QIAGEN entered into a definitive agreement to fully acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell sequencing market. The deal is expected to close in late 2025/December 2025 for an upfront payment of approximately $225 million in cash, plus up to $55 million in milestone payments.